Is EUPRAXIA PHARMACEUTICALS INC. (EPRX) Halal?

NASDAQ Healthcare Canada $413M
✓ HALAL
Confidence: 95/100
EUPRAXIA PHARMACEUTICALS INC. (EPRX) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.0% against the AAOIFI threshold of 30%, EUPRAXIA PHARMACEUTICALS INC. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
7.1%
/ 30%
0.0%
/ 30%
N/A ✓ HALAL
DJIM 0.0%
/ 33%
7.1%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
MSCI 0.2%
/ 33%
94.7%
/ 33%
0.7%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
7.1%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
FTSE 0.2%
/ 33%
94.7%
/ 33%
0.7%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-1.03
P/B Ratio
6.7
EV/EBITDA
-9.4
EV: $361M
Revenue
$0
Beta
1.4
High volatility
Current Ratio
15.1

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -68.8%
Return on Assets (ROA) -39.7%

Cash Flow & Balance Sheet

Operating Cash Flow-$29M
Free Cash Flow-$29M
Total Debt$154,362
Debt-to-Equity0.2
Current Ratio15.1
Total Assets$86M

Price & Trading

Last Close$6.85
50-Day MA$8.11
200-Day MA$6.39
Avg Volume227K
Beta1.4
52-Week Range
$2.68
$9.32

About EUPRAXIA PHARMACEUTICALS INC. (EPRX)

CEO
Dr. James A. Helliwell FRCPC, M.D.
Employees
49
Sector
Healthcare
Industry
Biotechnology
Country
Canada
Exchange
NASDAQ
Market Cap
$413M
Currency
USD

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is EUPRAXIA PHARMACEUTICALS INC. (EPRX) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), EUPRAXIA PHARMACEUTICALS INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is EUPRAXIA PHARMACEUTICALS INC.'s debt ratio?

EUPRAXIA PHARMACEUTICALS INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.2%.

What are EUPRAXIA PHARMACEUTICALS INC.'s key financial metrics?

EUPRAXIA PHARMACEUTICALS INC. has a market capitalization of $413M. Return on equity stands at -68.8%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.